Shattuck Labs, Inc. STTK · Stock Open Shattuck Labs, Inc. in new tab
Shattuck Labs, Inc. Analysis (STTK)
Is Shattuck Labs, Inc. a good investment? Shattuck Labs, Inc. (STTK) is currently trading at 6.11 USD. Market analysts have a consensus price target of 14.67 USD. This suggests a potential upside from current levels.
Earnings Schedule: Shattuck Labs, Inc. is expected to release its next earnings report on Nov. 10, 2026. The market consensus estimate for Forward EPS is -0.52.
Investor FAQ
Does Shattuck Labs, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Shattuck Labs, Inc.?
Shattuck Labs, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 10, 2026. The company currently has a trailing EPS of -0.44.
Company Profile
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Community Discussion